Array Biopharma Inc (NASDAQ:ARRY) insider Victor Sandor sold 156,016 shares of the stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $17.71, for a total value of $2,763,043.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Array Biopharma Inc (ARRY) opened at $18.05 on Monday. The company has a quick ratio of 6.17, a current ratio of 6.17 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $3,750.00, a P/E ratio of -23.44 and a beta of 1.80. Array Biopharma Inc has a 1-year low of $6.73 and a 1-year high of $18.78.
Array Biopharma (NASDAQ:ARRY) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $42.21 million during the quarter, compared to analysts’ expectations of $26.81 million. Array Biopharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. The company’s quarterly revenue was down 5.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.14) EPS. sell-side analysts anticipate that Array Biopharma Inc will post -0.87 earnings per share for the current fiscal year.
ARRY has been the subject of a number of recent research reports. Leerink Swann raised Array Biopharma from a “market perform” rating to an “outperform” rating in a research report on Monday, January 22nd. SunTrust Banks reissued a “buy” rating and issued a $20.00 price target on shares of Array Biopharma in a report on Tuesday, February 6th. Jefferies Group raised their price target on Array Biopharma to $13.00 and gave the company a “buy” rating in a report on Friday, December 22nd. Stifel Nicolaus raised their price target on Array Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Monday, January 22nd. Finally, BidaskClub raised Array Biopharma from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $16.43.
TRADEMARK VIOLATION WARNING: “Array Biopharma Inc (ARRY) Insider Victor Sandor Sells 156,016 Shares” was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.themarketsdaily.com/2018/03/12/array-biopharma-inc-arry-insider-victor-sandor-sells-156016-shares.html.
About Array Biopharma
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.